Commercial Insight: Cytotoxics - Generic Adversity Facing Major Cytotoxics
126 pages | Juillet 2005 |
IntroductionThere is a plethora of cytotoxics on the market but only a few dominate in terms of sales.
Yet, patents for major drugs are expected to expire in the short to mid term, and sales will d |
12 160,00 €
|
| |
| |
MarketWatch: Cancer
29 pages | Avril 2005 |
Datamonitor's Cancer MarketWatch is a one-stop news shop for time-pressed executives.
It provides monthly insight into the key events in the cancer therapeutic area.
MarketWatch features all the |
160,00 €
|
| |
| |
Anti-Angiogenics for Lung Cancer
1 pages | Janvier 2006 |
This Database Table is a one-page table of hard-to-find numerical information.
The Database Table is derived from a proprietary source and is meant to simply provide a high-level overview of specif |
80,00 €
|
| |
| |
Cancer Vaccines: Measuring Market Potential
232 pages | Octobre 2004 |
This report provides an overview of the emerging market for cancer vaccines and measures their potential impact on a number of cancer markets.
Vaccine product candidates are discussed within the co |
1 200,00 €
|
| |
| |
The Latin American Cancer Market Outlook to 2010
173 pages | Novembre 2005 |
The patient pool for cancer therapies is rising at a higher rate than the growth rate in population across the ten Latin American pharmaceutical markets, a trend primarily driven by the rising life ex |
2 443,75 €
|
| |
| |
Commercial Insight: Cancer Market Top 20 Drugs - Supportive Care Grows the Cancer Market
92 pages | Janvier 2005 |
IntroductionThe global cancer market is predicted to grow at a CAGR exceeding 10%.
However, a number of global and country-specific factors will support or threaten this trend including epidemiolog |
12 160,00 €
|
| |
| |
Market Leaders in Oncology 2004 - Roche and Genentech Continue to Blaze a Trail
71 pages | Janvier 2005 |
IntroductionRoche continues to lead the oncology sector, recording oncology sales of $5,719m in 2003.
This sector dominance is predicted to continue between 2004 and 2010, due to Roche's ability to |
3 040,00 €
|
| |
| |
Stakeholder Opinions: Chronic Leukemias - Curative Intent Raises the Bar
174 pages | Octobre 2005 |
IntroductionRecognizing that prolonging disease-free survival in chronic leukemia relies on the eradication of minimal residual disease has raised the bar for developers of novel pharmacotherapy.
I |
3 230,00 €
|
| |
| |
Stakeholder Insight: Breast Cancer - Changing Treatment Paradigms for Local and Locally Advanced Breast Cancer
199 pages | Avril 2005 |
IntroductionAnthracycline-based regimens and tamoxifen are well-established in the treatment of early-stage breast cancer.
In recent days, however, agents such as Sanofi-Aventis's Taxotere and Astr |
9 120,00 €
|
| |
| |
MarketWatch: Cancer
31 pages | Janvier 2005 |
Datamonitor's Cancer MarketWatch is a one-stop news shop for time-pressed executives.
It provides monthly insight into the key events in the cancer therapeutic area.
MarketWatch features all the |
160,00 €
|
| |
| |
